Compound class:
Synthetic organic
Comment: TBA-354 is a nitroimidazole-based antibacterial compound derived from pretomanid (PA-824) [1]. It has narrow-spectrum activity, inhibiting Mycobacterium tuberculosis and Mycobacterium bovis but not nontuberculous mycobacteria (NTM) or the Gram-positive and Gram-negative bacteria tested [2]. TBA-354 was under clinical development for the treatment of tuberculosis (TB), by the non-profit organisation TB Alliance (www.tballiance.org.za), but was discontinued in 2016 [3].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
5-({[(6S)-2-nitro-5H,6H,7H-imidazo[2,1-b][1,3]oxazin-6-yl]oxy}methyl)-2-[4-(trifluoromethoxy)phenyl]pyridine |
Database Links ![]() |
|
Specialist databases | |
Antibiotic DB
![]() |
TBA-354 |
Other databases | |
ChEMBL Ligand | CHEMBL1630563 |
GtoPdb PubChem SID | 500839956 |
PubChem CID | 49836057 |
Search Google for chemical match using the InChIKey | ZXSGSFMORAILEY-HNNXBMFYSA-N |
Search Google for chemicals with the same backbone | ZXSGSFMORAILEY |
UniChem Compound Search for chemical match using the InChIKey | ZXSGSFMORAILEY-HNNXBMFYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | ZXSGSFMORAILEY-HNNXBMFYSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
TBA-354 (links to external site)
Cat. No. HY-12485 |